Overview of NICE’s Elranatamab Managed Ac...

By João L. Carapinha

October 29, 2024

NICE recently recommended Elranatamab as an option for treating relapsed and refractory multiple myeloma in adults with a man...
HIQA’s Strategic Blueprint for Health Care Excellence: Draft Corporate ...
NICE Rejects Donanemab for NHS Use Due to Cost Concerns
Draft European Medicines Agency Strategy 2028: Enhancing Accessibility and In...
Bupa Launches Whole Genome Sequencing Pilot in UK
August 2024 Analysis of Türkiye’s Pharmaceutical Foreign Trade
Soaring Drug Prices in Europe: A Strain on Health Systems and Industry
EMA Competing Interests Policy for Scientific Committee Members
NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment
Depression and Life Satisfaction in Pregnant Women
Enhancing Child Mental Health Services with Digital Interventions
Cost-Effectiveness of Integrated Care for Children with Chronic Conditions
The Impact of Atrial Fibrillation on Quality of Life and Healthcare Costs